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psychostimulants, and received signiﬁcantly higher doses
of psychostimulants, suggesting disparities in AD/HD
treatment between boys and girls that may affect quality
of care.
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OBJECTIVES: Clinicians treating schizophrenia face
increasingly diverse populations, with different ethnic
groups having different medication adherence patterns.
The Texas Medicaid population with schizophrenia
includes large numbers of patients from several ethnic
groups, having broad use of the prevalent antipsychotic
medications within each ethnic group. The purpose of this
study was to assess the association between ethnicity and
adherence among Texas Medicaid clients with schizo-
phrenia, and to assess whether adherence within or across
ethnic groups differed depending on which antipsychotic
was used, after controlling for other factors. METHODS:
Texas Medicaid claims were retrieved for persons, age 21
to 65, diagnosed with schizophrenia or schizoaffective
disorder, initiating treatment with olanzapine (N = 1875),
risperidone (N = 982), or haloperidol (N = 726) between
1/1997 and 8/1998. For each of the three pairings of these
medications, the association between ethnicity (African
American, Mexican American, or Caucasian) or medica-
tion and days use of the medication in the year following
initiation was assessed using multivariate linear regres-
sion. Covariates included other patient demographics,
region, comorbid health conditions, and prior medication
and heath care resource use. RESULTS: Overall mean
adherence was 177 of 365 days (48.5%). African 
Americans and Mexican Americans were signiﬁcantly less
adherent than Caucasians in the haloperidol versus 
olanzapine and risperidone versus olanzapine compar-
isons (p < 0.05 for each comparison). For patients of all
ethnicities, olanzapine was associated with 19 more
adherent days than risperidone and 56 more adherent
days than haloperidol (p < 0.001 for each pairwise com-
parison). CONCLUSIONS: When other factors were 
controlled for 1) ethnicity was a signiﬁcant predictor of
adherence following initiation on an antipsychotic 
medication and 2) patients of all ethnicities were most
adherent when taking olanzapine, less adherent when
taking risperidone, and least adherent when taking
haloperidol.
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OBJECTIVES: The Quality of life in Depression Scale
(QLDS) is the most widely used measure of quality of 
life (QoL) in clinical trials and studies of depression. 
The instrument has been validated in 18 languages. The
instrument, which adopts the needs model, is highly 
sensitive to changes in QoL and is well accepted by
respondents. Since its development new statistical models
have been introduced into instrument development. The
present study was designed to adapt the QLDS using item
response theory in order to improve its measurement
properties further. METHODS: Existing datasets were
subjected to Rasch analysis to identify misﬁtting items
and to look for gaps in the range of measurement. As
weaknesses were identiﬁed at the extremes (very good 
or very poor QoL) additional interviews were conducted
with patients scoring either high or low on the QLDS and
new qualitative analyses were made of the 40 original
interview transcripts. Potential new items were added to
the QLDS and poorly performing ones removed. This
version was administered to samples of depressed patients
in the UK, US, France and Germany. The data were again
subjected to Rasch analysis and a ﬁnal version identiﬁed.
Its psychometric properties were then assessed in a second
postal survey. RESULTS: A 30-item version was identi-
ﬁed with little item misﬁt or differential item functioning
in the different countries. This version had excellent 
psychometric properties including reproducibility and
construct validity. The main gain was an increase in the
measurement range from 2.5 to 4.3 logits, an increase of
72%. CONCLUSIONS: The measurement properties of
the QLDS have been improved, ensuring it provides valid
scores on a unidimensional QoL scale. The increased
measurement range makes the instrument more suitable
for use across the full range of depression severity and
hence more valid for use in antidepressant maintenance
studies.
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OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and cost associated
